ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 2327

Differential Quantitative Profile of Myeloid Derived Suppressor Cells and Monocyte Subsets Relate to Clinical Phenotype and Disease Activity in Psoriatic Arthritis Patients

Jennifer Balderas Miranda1, Jiram Torres Ruiz2, Guillermo Guaracha Basañez3, Virginia Pascual Ramos4, Beatriz Alcalá-Carmona5, Yatzil Reyna-Juárez5, María José Ostos-prado5, Nancy R Mejía-Domínguez5, Guillermo Juarez-Vega6 and Diana Gomez-martin7, 1Universidad Nacional Autónoma de México, Ciudad de México, Mexico, 2INCMNSZ, Mexico, Federal District, Mexico, 3Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirón", Mexico City, Mexico, 4Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, 5Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, 6Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 7INCMNSZ, Mexico City, Federal District, Mexico

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: innate immunity, Monocytes/macrophages, Psoriatic arthritis

Session Information

Date: Monday, November 18, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The innate immune system not only participates in PsA pathogenesis but may also counteract with immunomodulatory elements. Proinflammatory and repairing roles according to monocyte subtype have been described in SpA and expansion of Myeloid Derived Suppressor Cells (MDSCs) has been shown in psoriasis. However, their quantitative profile and potential clinical associations in PsA have not been previously assessed, which is the main aim of the present study.

Methods: This cross-sectional study included 28 patients who fulfilled the Classification Criteria for Psoriatic Arthritis from a tertiary care centre in Mexico City. Granulocytic and monocytic MDSCs and monocyte subtypes (classical, non-classical and intermediate) from peripheral blood were analyzed by multiparametric flow cytometry and evaluated according to clinical manifestations and activity and damage scales (PASI, NAPSI, DAPSA, MDA, physician VAS). To evaluate potential differential cell compartments, particularly associated with PsA, samples from 19 psoriasis patients were compared. Quantitative variables according to clinical characteristics were compared with the Mann-Whitney U and Wilcoxon rank-sum tests. Correlations were assessed with Spearman’s ρ.

Results: Table 1 resumes demographic data of the study population. Significant differences of cell characteristics according to dermatological and musculoskeletal clinical features are shown in Table 2. Correlations between G-MDSCs, M-MDSCs, classical and non-classical monocytes and disease activity are depicted in Figure 1.
Regarding treatment, patients receiving leflunomide had stronger PDL-1 expression in G-MDSCs [2474 AU (2388-3843) vs 1928 (1621-2410) p= 0.014] as well as of arginase-1 (arg-1) in monocytic-MDSCs (M-MDSCs) [1919 AU (1234-1948) vs 1226 (1050-1886) p= 0.04]. In contrast, those under adalimumab showed a constant lowering effect on G-MDSCs, including percentage and absolute number [median 0.003% (0.002-0.004) vs 0.16% (0.04-0.25) p=0.021 and 0.075 cells/mm3 (0.054-0.096) vs 2.256 (0.61-5.18) p= 0.011], immature G-MDSCs [0.02 cells/mm3 (0.02-0.03) vs 1.34 (0.3-4.89) p= 0.016], arg-1 positive cells [ 0.0015% (0.0012 – 0.0017) vs 0.07 (0.009-0.23) p= 0.025] and PDL-1 positive G-MDSCs [9×10-4% (8×10-4-9.5×10-4) vs 0.03 (0.01-0.1) p= 0.034]. Additionally, ixekizumab was associated with a diminished amount of mature G-MDSCs [0.03 cells/mm3 (0.02-0.036) vs 0.1 (0.03-0.29) p= 0.04] and intermediate monocytes [4.1% (1.5-6) vs 9.5(5.4-17.7) p=0.02]. Psoriasis patients without musculoskeletal compromise showed increased G-MDSCs levels [0.15 cells/mm3 (0.08-0.41) VS 0.08 (0.02-0.1) p=0.04], but lower arg-1 levels in M-MDSCs [1164 AU (1008-1393) vs 1281(1110-1842) p= 0.02 ].

Conclusion: Our data shows that patients with PsA display a differential quantitative profile of MDSCs and monocytes, translating into particular clinical phenotypes and disease activity spectrum. Besides, DMARDs also play a role in modifying these subsets and might be useful as surrogate markers of biological efficacy. Longitudinal studies will be required to monitor the behaviour of these innate immune profile abnormalities in PsA patients.

Supporting image 1

Table 1. Main clinical and laboratory features according to the presence or absence of PsA

Supporting image 2

Table 2. Differential proportions of MDSCs and monocyte subtypes according to clinical manifestations in PsA patients

Supporting image 3

Figure 1. Correlation matrix between clinical and immunological parameters in PsA patients


Disclosures: J. Balderas Miranda: None; J. Torres Ruiz: None; G. Guaracha Basañez: None; V. Pascual Ramos: None; B. Alcalá-Carmona: None; Y. Reyna-Juárez: None; M. Ostos-prado: None; N. Mejía-Domínguez: None; G. Juarez-Vega: None; D. Gomez-martin: None.

To cite this abstract in AMA style:

Balderas Miranda J, Torres Ruiz J, Guaracha Basañez G, Pascual Ramos V, Alcalá-Carmona B, Reyna-Juárez Y, Ostos-prado M, Mejía-Domínguez N, Juarez-Vega G, Gomez-martin D. Differential Quantitative Profile of Myeloid Derived Suppressor Cells and Monocyte Subsets Relate to Clinical Phenotype and Disease Activity in Psoriatic Arthritis Patients [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/differential-quantitative-profile-of-myeloid-derived-suppressor-cells-and-monocyte-subsets-relate-to-clinical-phenotype-and-disease-activity-in-psoriatic-arthritis-patients/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differential-quantitative-profile-of-myeloid-derived-suppressor-cells-and-monocyte-subsets-relate-to-clinical-phenotype-and-disease-activity-in-psoriatic-arthritis-patients/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology